AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29072245 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended amoxicillin/clavulanic acid, 1 gram pre-operatively and then 625 mg BD for 5 days
Number of subjects: 135
Study 29072245 — intervention group
Group type: COMPARATOR
Intervention: Prophylactic amoxicillin/clavulanic acid, 1 gram pre-operatively only
Number of subjects: 135
Study 29072245 — intervention group
Group type: COMPARATOR
Intervention: Prophylactic levofloxacin, 1 gram pre-operatively only
Number of subjects: 135
Study 25527998 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT) as an adjunct to usual care
Number of subjects: 469
Study 25527998 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 469
Study 23935833 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo pills (described as Tylenol)
Number of subjects: 48
Study 23935833 — intervention group
Group type: EXPERIMENTAL
Intervention: Genuine acupuncture
Number of subjects: 48
Study 23935833 — intervention group
Group type: EXPERIMENTAL
Intervention: Sham acupuncture
Number of subjects: 48
Study 23935833 — intervention group
Group type: COMPARATOR
Intervention: Rest control
Number of subjects: 48
Study 21937811 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential therapy with pantoprazole 40 mg injection, twice daily for 2 weeks, followed by pantoprazole 40 mg oral administration, twice daily for 2 weeks
Number of subjects: 80
Study 21937811 — intervention group
Group type: COMPARATOR
Intervention: Pantoprazole 40 mg oral administration alone, twice daily for 4 weeks
Number of subjects: 80
Study 19737592 — intervention group
Group type: EXPERIMENTAL
Intervention: E. amoenum aqueous extract (500 mg/day)
Number of subjects: 44
Study 19737592 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 16495393 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel
Number of subjects: 1010
Study 16495393 — intervention group
Group type: COMPARATOR
Intervention: Vinorelbine
Number of subjects: 1010
Study 16495393 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab (in HER2/neu-positive subgroup)
Number of subjects: 1010
Study 16495393 — intervention group
Group type: COMPARATOR
Intervention: No trastuzumab (in HER2/neu-positive subgroup)
Number of subjects: 1010
Study 15246908 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH diet with 50 mmol sodium/2,100 kcal
Number of subjects: 0
Study 15246908 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH diet with 100 mmol sodium/2,100 kcal
Number of subjects: 0
Study 15246908 — intervention group
Group type: EXPERIMENTAL
Intervention: Typical American diet with 50 mmol sodium/2,100 kcal
Number of subjects: 0
Study 15246908 — intervention group
Group type: EXPERIMENTAL
Intervention: Typical American diet with 100 mmol sodium/2,100 kcal
Number of subjects: 0
Study 15246908 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH diet with 150 mmol sodium/2,100 kcal
Number of subjects: 0
Study 15246908 — intervention group
Group type: EXPERIMENTAL
Intervention: Typical American diet with 150 mmol sodium/2,100 kcal
Number of subjects: 0
Study 11032271 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg x kg(‐1) tramadol (Group 1)
Number of subjects: 60
Study 11032271 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (Group 2)
Number of subjects: 60
Study 9515971 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (mean dose 55 mg/day)
Number of subjects: 21
Study 9515971 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 8146588 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychophysical thresholds measured using a modified method of limits.
Number of subjects: 0
Study 8146588 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiological thresholds based on auditory steady-state potentials recorded from the scalp.
Number of subjects: 0
Study 8146588 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency stimuli (480 Hz) for physiological thresholds.
Number of subjects: 0
Study 8146588 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency stimuli (2000 Hz) for physiological thresholds.
Number of subjects: 0
Study 30908085 — intervention group
Group type: EXPERIMENTAL
Intervention: Gaze-Contingent Music Reward Therapy (GC-MRT)
Number of subjects: 12
Study 30052894 — intervention group
Group type: EXPERIMENTAL
Intervention: XANTUS
Number of subjects: 4020
Study 30052894 — intervention group
Group type: COMPARATOR
Intervention: ROCKET AF
Number of subjects: 4020
Study 27910117 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselling in primary care
Number of subjects: 0
Study 25362524 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg fluconazole and a single vaginal globule of fenticonazole (600 mg)
Number of subjects: 436
Study 25362524 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg fluconazole and a single vaginal globule of fenticonazole (600 mg) plus ten applications of a vaginal probiotic (Lactobacillus acidophilus, L. rhamnosus, Streptococcus thermophilus, L. delbrueckii subsp. bulgaricus) starting on the fifth day after azole treatment
Number of subjects: 436
Study 23557551 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren (150 mg/d)
Number of subjects: 40
Study 23557551 — intervention group
Group type: COMPARATOR
Intervention: Ramipril (5 mg/d)
Number of subjects: 40
Study 21241965 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg atorvastatin
Number of subjects: 30
Study 21241965 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg atorvastatin and 25 mg rofecoxib
Number of subjects: 30
Study 21241965 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 18703567 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 22
Study 18703567 — intervention group
Group type: EXPERIMENTAL
Intervention: Constant dual stimulation with GHRH/GHRP-2
Number of subjects: 22
Study 18703567 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine/GHRH
Number of subjects: 22
Study 18703567 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine/GHRH (another instance)
Number of subjects: 22
Study 15916222 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapalene 0.1% cream and gel
Number of subjects: 31
Study 15916222 — intervention group
Group type: COMPARATOR
Intervention: Tretinoin microsphere 0.04%
Number of subjects: 31
Study 15916222 — intervention group
Group type: COMPARATOR
Intervention: Tretinoin microsphere 0.1%
Number of subjects: 31
Study 15916222 — intervention group
Group type: COMPARATOR
Intervention: Negative control product
Number of subjects: 31
Study 12542558 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 179
Study 12542558 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan (6 mg subcutaneously)
Number of subjects: 179
Study 12542558 — intervention group
Group type: COMPARATOR
Intervention: Placebo injection
Number of subjects: 179
Study 12542558 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan (second intervention)
Number of subjects: 179
Study 12542558 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (second intervention)
Number of subjects: 179
Study 12542558 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan
Number of subjects: 179
Study 12542558 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 179
Study 10391673 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxybutynin XL (Ditropan XL)
Number of subjects: 0
Study 10391673 — intervention group
Group type: COMPARATOR
Intervention: Immediate-release oxybutynin
Number of subjects: 0
Study 10391673 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxybutynin XL
Number of subjects: 0
Study 9034759 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmaton Capsules (multivitamins plus ginseng extract G115)
Number of subjects: 625
Study 9034759 — intervention group
Group type: COMPARATOR
Intervention: Multivitamin capsules (without ginseng)
Number of subjects: 625
Study 2005078 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine a.m. (20 to 80 mg daily for 5 weeks)
Number of subjects: 120
Study 2005078 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine p.m. (20 to 80 mg daily for 5 weeks)
Number of subjects: 120
Study 6848406 — intervention group
Group type: EXPERIMENTAL
Intervention: chenodeoxycholic acid (13 mg/kg . day)
Number of subjects: 5
Study 6848406 — intervention group
Group type: EXPERIMENTAL
Intervention: ursodeoxycholic acid (13 mg/kg . day)
Number of subjects: 5
Study 31036108 — intervention group
Group type: EXPERIMENTAL
Intervention: TACE plus HIFU
Number of subjects: 90
Study 31036108 — intervention group
Group type: COMPARATOR
Intervention: TACE alone
Number of subjects: 90
Study 30395547 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic mild depressive symptoms (Class 2, 47% of the sample)
Number of subjects: 1172
Study 30395547 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistent moderate/severe depressive symptoms (Class 3, 15% of the sample)
Number of subjects: 1172
Study 30395547 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal or no depressive symptoms (Class 1, 38% of the sample)
Number of subjects: 1172
Study 27442803 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl iontophoretic transdermal system (ITS)
Number of subjects: 1459
Study 27442803 — intervention group
Group type: COMPARATOR
Intervention: Morphine intravenous patient-controlled analgesia (iv. PCA)
Number of subjects: 1459
Study 24503689 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-door laminoplasty
Number of subjects: 92
Study 24503689 — intervention group
Group type: COMPARATOR
Intervention: French-door laminoplasty
Number of subjects: 92
Study 22410815 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet soda (240 mL cola-flavored caffeine-free)
Number of subjects: 44
Study 22410815 — intervention group
Group type: COMPARATOR
Intervention: Carbonated water
Number of subjects: 44
Study 20112525 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic pressure (15 msw, 253 kPa)
Number of subjects: 22
Study 20112525 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2 msw, 120 kPa)
Number of subjects: 22
Study 17573591 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported STD in the last 6 months
Number of subjects: 293
Study 17573591 — intervention group
Group type: EXPERIMENTAL
Intervention: Condom use with male clients
Number of subjects: 293
Study 17573591 — intervention group
Group type: EXPERIMENTAL
Intervention: Unprotected sex with boyfriends
Number of subjects: 293
Study 17573591 — intervention group
Group type: EXPERIMENTAL
Intervention: Unprotected sex with one-night-stand partners
Number of subjects: 293
Study 17573591 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with condom use
Number of subjects: 293
Study 15370397 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 2% azithromycin
Number of subjects: 40
Study 15370397 — intervention group
Group type: COMPARATOR
Intervention: Topical 2% erythromycin
Number of subjects: 40
Study 11241254 — intervention group
Group type: EXPERIMENTAL
Intervention: Strontium only (strontium 4 Mci in Week 1 and Week 12)
Number of subjects: 29
Study 11241254 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinblastine 4 mg/m(2) per week for 3 weeks then 1 week off and estramustine, 10 mg/kg per day
Number of subjects: 29
Study 11241254 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of CHEMO and STRONT
Number of subjects: 29
Study 11241254 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 29
Study 10997166 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 i.u. of intrathecal human anti-tetanus immunoglobulin (TIG)
Number of subjects: 36
Study 10997166 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure mimicking lumbar puncture
Number of subjects: 36
Study 7798415 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 micrograms OTFC
Number of subjects: 0
Study 7798415 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 micrograms OTFC
Number of subjects: 0
Study 7798415 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 2722310 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide, 20 mg
Number of subjects: 12
Study 2722310 — intervention group
Group type: EXPERIMENTAL
Intervention: BRL 24924, 2 mg
Number of subjects: 12
Study 2722310 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 31099217 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture group A (dilatational wave, 2 Hz/100 Hz)
Number of subjects: 120
Study 31099217 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture group B (continuous wave, 2 Hz)
Number of subjects: 120
Study 31099217 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture group C (continuous wave, 100 Hz)
Number of subjects: 120
Study 28638029 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantogam (hopantenic acid) administered in tablets (250 mg) at a therapeutic dose of 30 mg/kg of body mass, divided into 2 doses, during 4 months.
Number of subjects: 100
Study 28638029 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 28638029 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantogam (hopantenic acid)
Number of subjects: 100
Study 25525862 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Exercise (HIE)
Number of subjects: 10
Study 23472599 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral hormone therapy (n = 26)
Number of subjects: 76
Study 23472599 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal hormone therapy (n = 20)
Number of subjects: 76
Study 23472599 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 30)
Number of subjects: 76
Study 21809025 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with FOLFOX regimen (oxaliplatin 100 mg/m² on day 1, leucovorin 200 mg/m² on day 1, 5-fluorouracil 2000 mg/m² as a 48-h continuous infusion for up to six courses in the 1st year after transplantation)
Number of subjects: 95
Study 21809025 — intervention group
Group type: COMPARATOR
Intervention: Control group (no adjuvant chemotherapy)
Number of subjects: 95
Study 19783561 — intervention group
Group type: EXPERIMENTAL
Intervention: Praneem polyherbal vaginal tablets
Number of subjects: 99
Study 19783561 — intervention group
Group type: COMPARATOR
Intervention: Betadine vaginal pessary
Number of subjects: 99
Study 16779513 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin (2,000,000 KIU starting dose, followed by 500,000 KIU per hour)
Number of subjects: 35
Study 16779513 — intervention group
Group type: COMPARATOR
Intervention: Placebo (NaCl 0.9%)
Number of subjects: 35
Study 16779513 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 35
Study 16779513 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 14569109 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfacalcidol 0.5 micro g by mouth daily
Number of subjects: 40
Study 14569109 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 40
Study 11016328 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin
Number of subjects: 161
Study 11016328 — intervention group
Group type: COMPARATOR
Intervention: Diltiazem
Number of subjects: 161
Study 8792262 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-mediated intervention with normally developing peers, matched by sex and age, details on dosage and duration not available.
Number of subjects: 0
Study 8792262 — intervention group
Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 0
Study 1293915 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined multidrug treatment (MDT) and immunotherapy with heat killed Mycobacterium w or BCG, administered intradermally every six months.
Number of subjects: 0
Study 1293915 — intervention group
Group type: COMPARATOR
Intervention: Multidrug treatment (MDT) alone
Number of subjects: 0
Study 3838188 — intervention group
Group type: EXPERIMENTAL
Intervention: MOPP chemotherapy plus extensive radiotherapy (mantle and paraaortic areas)
Number of subjects: 335
Study 3838188 — intervention group
Group type: COMPARATOR
Intervention: MOPP chemotherapy plus involved field radiotherapy
Number of subjects: 335
Study 3838188 — intervention group
Group type: EXPERIMENTAL
Intervention: MOPP chemotherapy plus extensive radiotherapy
Number of subjects: 335
Study 30973337 — intervention group
Group type: EXPERIMENTAL
Intervention: SFSW intervention (Web-based training program with 11 weekly themes and associated telephone sessions)
Number of subjects: 1114
Study 30384087 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal-narrative intervention
Number of subjects: 1449
Study 30384087 — intervention group
Group type: COMPARATOR
Intervention: No-intervention control
Number of subjects: 1449
Study 28376080 — intervention group
Group type: EXPERIMENTAL
Intervention: CAP-CRT
Number of subjects: 114
Study 28376080 — intervention group
Group type: COMPARATOR
Intervention: GEM-CRT
Number of subjects: 114
Study 25220844 — intervention group
Group type: EXPERIMENTAL
Intervention: Tyrosine (300 mg/kg)
Number of subjects: 78
Study 25220844 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study 23609132 — intervention group
Group type: EXPERIMENTAL
Intervention: Marijuana (1.98% THC)
Number of subjects: 30
Study 23609132 — intervention group
Group type: EXPERIMENTAL
Intervention: Marijuana (3.56% THC)
Number of subjects: 30
Study 23609132 — intervention group
Group type: EXPERIMENTAL
Intervention: Dronabinol (20 mg)
Number of subjects: 30
Study 23609132 — intervention group
Group type: EXPERIMENTAL
Intervention: Marijuana (1.98%, 3.56%)
Number of subjects: 30
Study 21890886 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% w/v hydroxyethyl starch solution (HES)
Number of subjects: 60
Study 21890886 — intervention group
Group type: COMPARATOR
Intervention: Hartmann (crystalloid) solution (HS)
Number of subjects: 60
Study 21890886 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine infusion
Number of subjects: 60
Study 19695776 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet treatment group (8 weeks of online modules including relaxation training, cognitive strategies, parent operant techniques, communication strategies, and sleep and activity interventions)
Number of subjects: 48
Study 19695776 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet treatment group
Number of subjects: 48
Study 19695776 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group (current medical care only)
Number of subjects: 48
Study 17908057 — intervention group
Group type: EXPERIMENTAL
Intervention: Periosteal stimulation therapy (PST)
Number of subjects: 88
Study 17908057 — intervention group
Group type: COMPARATOR
Intervention: Control PST
Number of subjects: 88
Study 15472602 — intervention group
Group type: EXPERIMENTAL
Intervention: Inflow from the common femoral artery (CFA)
Number of subjects: 160
Study 15472602 — intervention group
Group type: COMPARATOR
Intervention: Inflow from below the common femoral artery
Number of subjects: 160
Study 12426738 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose spiral CT screening
Number of subjects: 0
Study 9680783 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole
Number of subjects: 26
Study 9231947 — intervention group
Group type: EXPERIMENTAL
Intervention: Org 10172 (1250 anti‐Xa Units s.c. once daily)
Number of subjects: 179
Study 9231947 — intervention group
Group type: COMPARATOR
Intervention: Heparin sodium (5000 IU s.c. twice daily)
Number of subjects: 179
Study 9231947 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 179
Study 2493376 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics plus intravenous gammaglobulin (i.v. IgG)
Number of subjects: 33
Study 2493376 — intervention group
Group type: COMPARATOR
Intervention: Antibiotics (cefataxim and amikacin)
Number of subjects: 33
Study 29371246 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.8 mg daily folic acid + 10 mg enalapril
Number of subjects: 16413
Study 29371246 — intervention group
Group type: COMPARATOR
Intervention: 10 mg enalapril
Number of subjects: 16413
Study 29132440 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate, intensive periodontal treatment (n=30)
Number of subjects: 60
Study 29132440 — intervention group
Group type: COMPARATOR
Intervention: Delayed treatment (n=30)
Number of subjects: 60
Study 26016052 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological therapy and CPAP (Group B)
Number of subjects: 36
Study 26016052 — intervention group
Group type: COMPARATOR
Intervention: Pharmacological therapy only (Group A)
Number of subjects: 36
Study 23131570 — intervention group
Group type: EXPERIMENTAL
Intervention: Sea buckthorn oil (SBO) extract, 4 capsules per day, each containing 500 mg, for 8 weeks
Number of subjects: 45
Study 23131570 — intervention group
Group type: COMPARATOR
Intervention: Placebo, 4 capsules per day for 8 weeks
Number of subjects: 45
Study 23131570 — intervention group
Group type: EXPERIMENTAL
Intervention: Sea buckthorn oil (SBO) extract
Number of subjects: 45
Study 23131570 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 22283033 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc (5 mg), Iron (6.25 mg), Folic Acid (25 microg) supplementation
Number of subjects: 367
Study 22283033 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined micronutrient supplements (Zinc, Iron, Folic Acid)
Number of subjects: 367
Study 22283033 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 367
Study 20128376 — intervention group
Group type: EXPERIMENTAL
Intervention: valsartan/amlodipine 80/5 mg once daily
Number of subjects: 0
Study 20128376 — intervention group
Group type: COMPARATOR
Intervention: monotherapy (amlodipine 5 mg or valsartan 80 mg)
Number of subjects: 0
Study 16401691 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (20 mg for three weeks, 40 mg for three weeks)
Number of subjects: 23
Study 16401691 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 15230994 — intervention group
Group type: EXPERIMENTAL
Intervention: High beta-carotene concentration
Number of subjects: 652
Study 15230994 — intervention group
Group type: COMPARATOR
Intervention: Low beta-carotene concentration
Number of subjects: 652
Study 15230994 — intervention group
Group type: COMPARATOR
Intervention: alpha-Carotene, beta-cryptoxanthin, lycopene, lutein, zeaxanthin
Number of subjects: 652
Study 10894590 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 weeks of ribavirin/interferon
Number of subjects: 0